Description

United Therapeutics: The $2 Billion Drug That Could Quietly Become A $10 Billion Franchise!

United Therapeutics has moved sharply higher after fresh Phase 3 data strengthened the case for Tyvaso in idiopathic pulmonary fibrosis, or IPF, but the bigger story may not be the single trial result itself. What stands out is that Tyvaso increasingly looks less like one successful pulmonary hypertension medicine and more like a franchise that keeps expanding through new indications, new delivery formats, and higher patient utility. The current business is already substantial, with Tyvaso generating $1.88 billion in 2025 sales and remaining the company’s main commercial engine. Now, a positive second pivotal IPF study, management’s plan to seek regulatory review, and a broader push around treprostinil-based formats suggest the revenue base could keep widening without the company needing to rely on a brand-new molecule to drive the next leg of growth.